A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) IN PATIENTS WITH LIVER-DOMINANT METASTATIC COLORECTAL CANCER
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms SIRTCI
- 16 Aug 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2024.
- 16 Aug 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.
- 01 Jul 2022 The trial has included 10 out of the 52 planned patients as per trial design published in the Digestive and Liver Disease